Literature DB >> 28493410

Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.

Hyeyoon Chang1, Wonkyung Jung2, Aeree Kim1, Han Kyeom Kim1, Wan Bae Kim3, Ji Hoon Kim4, Baek-Hui Kim1.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies and causes of death worldwide. In this study, we assessed the correlation between clinicopathologic factors with programmed cell death protein 1 (PD-1) and programmed cell death ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) expressions. Furthermore, we analyzed the prognostic significance of these proteins in a subgroup of patients. We retrospectively evaluated the PD-1, PD-L1, and CTLA-4 expressions in 294 HCC tissue microarray samples using immunohistochemistry. PD-1 and PD-L1 expressions were significant related to high CD8+ tumor-infiltrating lymphocytes (TILs) (r = 0.664, p < 0.001 and r = 0.149, p = 0.012). Only high Edmondson-Steiner grade was statistically related to high PD-1 expression. High PD-L1 expression was demonstrated as an independent poor prognostic factor for disease-free survival in addition to previous known factors, size >5 cm and serum albumin ≤3.5 g/dL in high CD8+ TILs group. We have demonstrated that the combined high expression of PD-L1 and CD8+ TIL is an important prognostic factor related to the immune checkpoint pathway in HCC and furthermore, there is a possibility that it could be used as a predictor of therapeutic response. Also, this result would be helpful in evaluating the applicable group of PD-1/PD-L1 blocking agent for HCC patients.
© 2017 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Hepatocellular carcinoma; cytotoxic T lymphocyte-associated molecule-4; programmed cell death ligand-1; programmed cell death protein 1; tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2017        PMID: 28493410     DOI: 10.1111/apm.12703

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  23 in total

1.  Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody.

Authors:  Ziwei Li; Bin Li; Dan Peng; Haiyan Xing; Guanying Wang; Pan Li; Jiming Wang; George Ye; Jianhong Chen
Journal:  Int J Oncol       Date:  2018-04-04       Impact factor: 5.650

Review 2.  Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.

Authors:  Amblessed E Onuma; Hongji Zhang; Hai Huang; Terence M Williams; Anne Noonan; Allan Tsung
Journal:  Gene Expr       Date:  2020-04-27

Review 3.  Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.

Authors:  Zuyuan Lin; Di Lu; Xuyong Wei; Jianguo Wang; Xiao Xu
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

4.  Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Authors:  Kohei Shigeta; Meenal Datta; Tai Hato; Shuji Kitahara; Ivy X Chen; Aya Matsui; Hiroto Kikuchi; Emilie Mamessier; Shuichi Aoki; Rakesh R Ramjiawan; Hiroki Ochiai; Nabeel Bardeesy; Peigen Huang; Mark Cobbold; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2019-10-14       Impact factor: 17.425

5.  Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.

Authors:  Lin Sun; Luwen Mu; Jing Zhou; Wenjie Tang; Linqi Zhang; Sidong Xie; Jingbiao Chen; Jin Wang
Journal:  Cancer Immunol Immunother       Date:  2021-05-16       Impact factor: 6.968

6.  Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.

Authors:  Ramy R Saleh; Jordan L Scott; Nicholas Meti; Danielle Perlon; Rouhi Fazelzad; Alberto Ocana; Eitan Amir
Journal:  Mol Diagn Ther       Date:  2022-02-01       Impact factor: 4.074

Review 7.  Immune checkpoint therapy in liver cancer.

Authors:  Feng Xu; Tianqiang Jin; Yuwen Zhu; Chaoliu Dai
Journal:  J Exp Clin Cancer Res       Date:  2018-05-29

8.  Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma.

Authors:  Hyung-Wook Chun; Ran Hong
Journal:  Oncol Lett       Date:  2019-04-05       Impact factor: 2.967

9.  Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis.

Authors:  Gao-Min Liu; Xu-Gang Li; Yao-Min Zhang
Journal:  Cancer Cell Int       Date:  2019-01-29       Impact factor: 5.722

Review 10.  Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.

Authors:  Archana Rastogi
Journal:  World J Gastroenterol       Date:  2018-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.